NexImmune Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Gaithersburg MD United States (2011)

Organization Overview

First Clinical Trial
2020
NCT04284228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

NexImmune Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

nexi-001 t cells (2 trials)

Drugs in Phase 1 Trials (3)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

nexi-003 t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Myeloid, Acute (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4